Atosiban

證據等級: L5

預測適應症: 10 個

ATOSIBAN: From Preterm Labor to Primary Hereditary Glaucoma

One-Sentence Summary

Atosiban is a competitive oxytocin/vasopressin V1A receptor antagonist approved in multiple countries as a tocolytic agent to suppress uterine contractions and delay preterm birth. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, a rare genetic eye disease caused by mutations such as MYOC and OPTN. This prediction is currently supported by 0 clinical trials and 0 publications specifically addressing this indication — it remains a model-prediction-only finding with no experimental validation.

Quick Overview

Item	Content
Original Indication	Preterm labor (tocolysis)
Predicted New Indication	Primary Hereditary Glaucoma
TxGNN Prediction Score	99.92%
Evidence Level	L5
Saudi Arabia Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Atosiban acts as a competitive antagonist at oxytocin (OT) and vasopressin V1A receptors. In preterm labor, it blocks OT receptors on uterine smooth muscle, suppressing myometrial contractions. Beyond the reproductive system, OT receptors have been identified in ocular tissues including the ciliary body and the trabecular meshwork — structures that govern aqueous humor dynamics and intraocular pressure (IOP). This anatomical finding provides a theoretical foothold for the prediction: if OT signaling influences IOP regulation, an OT receptor antagonist might in principle modulate this pathway.

However, primary hereditary glaucoma is fundamentally a genetic disease. Pathogenic mutations in MYOC, OPTN, FOXC1, and related genes alter trabecular meshwork development and protein homeostasis, driving elevated IOP through structural and molecular mechanisms that are distinct from OT receptor signaling. Whether atosiban's receptor blockade could meaningfully intersect with these genetic pathways is not established, and the directionality of any IOP effect remains entirely unknown.

The high TxGNN score (99.92%) at rank 1805 is most likely attributable to knowledge graph neighborhood effects — a clustering of IOP-related disease nodes near vasopressin/OT pathway nodes — rather than a validated mechanistic connection. The pipeline's own annotation confirms this concern, noting that no data exists to support OT antagonism as a strategy for hereditary glaucoma and that gene-mutation-driven pathogenesis weakens the mechanistic rationale.

Clinical Trial Evidence

Currently no related clinical trials registered for Primary Hereditary Glaucoma.

Literature Evidence

Currently no related literature available for Primary Hereditary Glaucoma.

Saudi Arabia Market Information

Atosiban has not been approved for marketing in Saudi Arabia. No product authorizations are on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical, preclinical, or mechanistic evidence directly linking atosiban to primary hereditary glaucoma management. The prediction score reflects knowledge graph topology rather than pharmacological plausibility — and the genetic etiology of hereditary glaucoma (MYOC/OPTN mutations affecting trabecular meshwork architecture) does not align with OT receptor antagonism as a therapeutic strategy.

To proceed, the following is needed:

Preclinical studies examining whether OT receptor blockade alters intraocular pressure in validated animal models of hereditary glaucoma
Molecular characterization of OT receptor expression and function in trabecular meshwork cells carrying MYOC/OPTN mutations
Mechanistic studies clarifying the downstream effect of OT signaling on aqueous humor outflow resistance
Full MOA and safety data for atosiban (currently unavailable — TFDA package insert parsing and DrugBank API query required)
Comparative review of the broader TxGNN glaucoma cluster (ranks 1805–1828) to assess whether the prediction represents a genuine signal or a systematic false-positive arising from graph neighborhood effects
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.